"Daunorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
| Descriptor ID |
D003630
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200 D04.615.562.050.200 D09.408.051.059.200
|
| Concept/Terms |
Daunorubicin- Daunorubicin
- Daunomycin
- Rubomycin
- Dauno-Rubidomycine
- Dauno Rubidomycine
- Rubidomycin
|
Below are MeSH descriptors whose meaning is more general than "Daunorubicin".
Below are MeSH descriptors whose meaning is more specific than "Daunorubicin".
This graph shows the total number of publications written about "Daunorubicin" by people in this website by year, and whether "Daunorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2001 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Daunorubicin" by people in Profiles.
-
No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. Pediatr Blood Cancer. 2019 06; 66(6):e27681.
-
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA. 2015 Aug 25; 314(8):811-22.
-
Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study. Leuk Res. 2015 Aug; 39(8):812-7.
-
Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. Cancer Chemother Pharmacol. 2014 Oct; 74(4):831-8.
-
Augmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8.
-
Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer. 2014 Jun 15; 120(12):1818-29.
-
Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma. Pediatr Blood Cancer. 2014 May; 61(5):810-4.
-
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle. 2012 Jun 15; 11(12):2314-26.
-
Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407. Pediatr Blood Cancer. 2012 Nov; 59(5):834-9.
-
Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Cancer. 2010 Nov 15; 116(22):5272-8.